Respiratory inhaler are used with a complementary spacer or holding chamber device in order to decrease deposition in the mouth and throat and to mitigate the need for precise synchronization of the start of inhalation with actuation of the device.
The global Respiratory Inhaler Market is estimated to account for US$ 32,921.8 Mn in terms of value and is expected to reach US$ 46,984.1 Mn by the end of 2027.
Global Respiratory Inhaler Market: Drivers
Increasing adoption of combination therapies such as triple combination therapy for Chronic Obstructive Pulmonary Disease (COPD) patients is expected to boost growth of the global Respiratory Inhaler Market over the forecast period. The demand for combined therapies is increasing due to associated benefits such as more reliable in complex patients, increased efficacy, and easy reimbursement policies associated with the therapy.
Global Respiratory Inhaler Market: Opportunities
Smart inhaler technology is a novel technology developed to help the patients in keeping a check on their doses and offers various other features. Some devices with smart inhaler technology are capable to read environment pollution, in terms of air quality, and it may alert the patient on presence of triggers of asthma in the air. Propeller Health, a U.S.-based company started supplementing medicines with this technology. They have connected an inhaler with Bluetooth transmitter to provide connectivity to the smartphone. This technology can keep a track of a patient’s frequency of suffering an asthmatic attack and causes behind the triggers and provide it to their respective healthcare professional.
Global Respiratory Inhaler Market: Restraints
Increasing adoption of respiratory inhaler devices has led to high demand for pulmonologist, physicians, and nurses to enable or ensure correct usage of inhalers and nebulisers and to provide adequate training to patients. However, lack of skilled pulmonologist and physicians, especially in developing regions is expected to hamper growth of the market to some extent.
The metered dose inhaler sub-segment in product type segment in the global Respiratory Inhaler Market was valued at US$ 22,360.9 Mn in 2018 and is expected to reach US$ 33,825.0 Mn by 2027 at a CAGR of 4.5% during the forecast period.
Metered-dose inhaler delivers specific dose of medication in aerosol form. The metered-dose inhaler was the first marketed inhaler in 1950s and is still the most common inhaler used across the globe. Moreover, its low cost compared to other advanced inhalers such as dry powder inhaler and nebulizer, gives it a competitive advantage, especially in developing economies inducing India, China, and Brazil, where cost is one of the critical factors.
The manually operated inhaler devices sub segment in the technology segment held dominant position in the global Respiratory Inhaler Market in 2018, accounting for 93.1% share in terms of value, followed by digitally operated inhaler devices.
Manual inhalers are the most common type of respiratory inhalers. In manual inhalers, medication is stored in pressurized canister in solution form, which also contains a propellant. The most common propellant used is hydrofluoroalkane (HFA), which is environment friendly.
The Asthma sub segment in disease indication segment held dominant position in the global Respiratory Inhaler Market in 2018, accounting for 60.4% share in terms of value, followed by COPD and pulmonary arterial hypertension, respectively.
Product launches for the treatment of asthma is expected to support growth of the market over the forecast period. For instance, In January 2017, U.S. FDA approved AstraZeneca’s Symbicort (budesonide/formoterol fumarate dihydrate), a metered-dose inhaler for the treatment of asthma in pediatric patients aged six to 12 years.
The market is witnessing increasing R&D related to proper use of inhaler device. For instance, in September 2018, researchers from University of Helsinki, Finland, reported investigation of non-verbal, demonstrational videos as a method of teaching inhaler naïve individuals how to use a dry powder inhaler (DPI).
The market is also witnessing launch of devices to track usage pattern of metered-dose inhalers (MDI). For instance, in November 2019, Lupin Ltd. launched a device – Adhero – to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.
Global Respiratory Inhaler Market: Competitive Landscape
Major players operating in the global Respiratory Inhaler Market include, AstraZeneca plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.
Global Respiratory Inhaler Market: Key Developments
Key players in the market are focused on launching smart inhaler devices to expand their product portfolio. For instance, in January 2019, FindAir, a European company developing digital systems for asthma and COPD control, launched its commercial smart inhaler device FindAir ONE
Key players in the market are also focused on receiving certification from regulatory bodies for their novel inhaler devices. For instance, in September 2019, Novartis International AG’s Concept1 inhaler received certification under the new EU Medical Devices Regulation (MDR)
“*” marked represents similar segmentation in other categories in the respective section.